TACSTD2 and neoplasm: This trispecific T cell engager comprises three antibody-derived binding domains on a single polypeptide chain: one to extend half-life through albumin binding, a second for T cell engagement via CD3 binding, and a third targeting Trop2-positive tumor cells 74.